
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc. reported operating expenses of $36.4 million, reflecting an increase of $2.0 million year-over-year, while its revenue for the third quarter exceeded consensus expectations and prompted management to raise the mid-point of its guidance. The company anticipates gross margins for 2025 to be between 76-77%, an increase from previous guidance, indicating potential for improved profitability. Additionally, favorable factors such as an accelerated installed base growth of light adjustable lenses (LDD), enhanced utilization, increased volumes of light adjustable lenses (LAL), and overall margin improvement could serve as significant catalysts for RxSight's financial performance moving forward.
Bears say
RxSight Inc. is experiencing a decline in key performance metrics, with monthly utilization of light adjustable lenses (LALs) dropping to 8.0 per lens delivery device (LDD) in 3Q25, down from 8.7 in 2Q25 and 10.1 in 3Q24. The company has revised its fiscal year 2026 revenue guidance to $120-135 million, indicating a potential revenue decline of up to 11% year-over-year, which falls short of both internal and market expectations. Additionally, RxSight is facing increased pressures on gross margins due to higher-cost inventory, which is projected to lead to sequential revenue contraction into 2026.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares